Clinical Trials Browser

Phase 1 × Active not recruiting × daratumumab × Clear all

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04910568 2025-12-24

CAMMA 1

Phase 1 Active not recruiting

Multiple Myeloma

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT04667663 2025-01-09

CPD-DARA

Phase 1 Active not recruiting

Multiple Myeloma